eflornithine (ornidyl) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Eflornithine is a prescription drug indicated in the treatment of facial hirsutism (excessive hair growth). Eflornithine hydrochloride cream for topical application is intended for use in women suffering from facial hirsutism and is sold by Allergan, Inc. under the brand name Vaniqa. Besides being a non-mechanical and non-cosmetic treatment, eflornithine is the only non-hormonal and non-systemic prescription option available for women who suffer from facial hirsutism. Eflornithine for injection against sleeping sickness was manufactured by Sanofi Aventis and sold under the brand name Ornidyl in the USA. It is now discontinued. Eflornithine is on the World Health Organization's List of Essential Medicines. Eflornithine prevents hair growth by inhibiting the anagen phase of hair production. This occurs by eflornithine irreversibly binding (also called suicide inhibition) to ornithine decarboxylase (ODC) and physically preventing the natural substrate ornithine from accessing the active site.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral, Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$3.5329
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-(difluoromethyl)ornithine | alpha-(difluoromethyl)-dl-ornithine | alpha-difluoromethylornithine | dfmo | dfmo hcl | difluoromethylornithine | difluromethylornithine | eflornithine | eflornithine hcl | eflornithine hdyrochloride | eflornithine hydrochloride | eflornithine hydrochloride anhydrous | eflornithine hydrochloride hydrate | eflornithine hydrochloride monohydrate | elfornithine | mdl-71782a | ornidyl | (rs)-2,5-diamino-2-(difluoromethyl)pentanoic acid | vaniqa | α-difluoromethylornithine

Organizations (45)

Research & Development (42)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Hirsutism (approved 2000)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Adenomatous Polyposis Coli (Phase 3)

Adenomatous Polyps (Phase 2)

Astrocytoma (Phase 3)

Colorectal Neoplasms (Phase 3)

Diabetes Mellitus, Type 1 (Phase 1)

Esophageal Neoplasms (Phase 2)

Glioma (Early Phase 1)

Hirsutism (Phase 4)

Intestinal Neoplasms (Phase 2)

Melanoma (Phase 3)

Neoplasms (Phase 2)

Neuroblastoma (Phase 2)

Organ Transplantation (Phase 2)

Precancerous Conditions (Phase 3)

Prostatic Neoplasms (Phase 2)

Skin Diseases (Phase 4)

Skin Neoplasms (Phase 2)

Sleep Disorders, Intrinsic (Phase 2/Phase 3)

Stomach Neoplasms (Phase 2)

Trypanosomiasis ()

Trypanosomiasis, African (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 41
  • # of Trial Organizations: 42

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue